<PAGE>
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
______________
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15 (d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported) January 16, 2001
------------------
COMMONWEALTH BIOTECHNOLOGIES, INC.
----------------------------------
(Exact Name of Registrant as Specified in Charter)
<TABLE>
<S> <C> <C>
Virginia 001-13467 56-1641133
-------------------------- --------- ----------
(State or Other (Commission File Number) (IRS Employer
Jurisdiction of Identification No.)
Incorporation)
</TABLE>
601 Biotech Drive, Richmond, Virginia 23235
---------------------------------------------------------
(Address of Principal Executive Offices) (Zip Code)
Registrant's telephone number, including area code: (804) 648-3820
---------------
N/A
---------------------------------------------------------------------
(Former Name or Former Address, if Changed Since Last Report)
<PAGE>
Item 5. Other Events.
On January 16, 2001, the Registrant announced the purchase of the current
contracts and the rights to the pending contracts of the Drug Development Group
of SRA Life Sciences, Inc. A copy of the press release relating to the
announcement is attached as an exhibit hereto.
Item 7. Financial Statements and Exhibits.
(a) Financial Statements of Businesses Acquired.
Not applicable.
(b) Pro Forma Financial Information.
Not applicable.
(c) Exhibits.
99.1 Press Release, dated January 16, 2001, relating to the Registrant's
acquisition of the current contracts and the rights to the
pending contracts of the Drug Development Group of SRA Life
Sciences, Inc.
2
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
COMMONWEALTH BIOTECHNOLOGIES, INC.
By: /s/ Richard J. Freer, Ph.D.
----------------------------------------
Richard J. Freer, Ph.D.
Chairman
January 16, 2001
3
<PAGE>
EXHIBIT INDEX
Number Description of Exhibit
------ ----------------------
99.1 Press Release, dated January 16, 2001, relating to the
Registrant's acquisition of the current contracts and the rights
to the pending contracts of the Drug Development Group of SRA
Life Sciences, Inc.
